

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

ARCD:390US

10/782,401

Applicant

Philip Ashton-Rickardt

Filing Date:

February 19, 2004

Group:

1614

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BF	C1	Al-Khunaizi <i>et al.</i> , "The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases," <i>Biochemistry</i> , 41:3189-3199, 2002.
	C2	Borner and Monney, "Apoptosis without caspases: an inefficient molecular guillotine?" <i>Cell Death Diff.</i> , 6:497-507, 1999.
	C3	Cooley <i>et al.</i> , "The serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through efficient reactions at two active sites," <i>Biochemistry</i> , 40(51):15762-15770, 2001.
	C4	Ferri and Kroemer, "Organelle-specific initiation of cell death pathways," <i>Nat. Cell Biol.</i> , 3:E255-E263, 2001.
	C5	Foghsgaard <i>et al.</i> , "Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor," <i>J. Cell. Biol.</i> , 153(5):999-1009, 2001.
	C6	Goossens <i>et al.</i> , "Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity," <i>Proc. Natl. Acad. Sci., USA</i> , 92:8115-8119, 1995.
↓	C7	Guicciardi <i>et al.</i> , "Cathepsin B contributes to TNF- α -mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c," <i>J. Clin. Invest.</i> , 106(9):1127-1137, 2000.
BF	C8	Hampson <i>et al.</i> , "Identification of a serpin specifically expressed in multipotent and bipotent hematopoietic progenitor cells and in activated T cells," <i>Blood</i> , 89(1):108-118, 1997.

25400625.1

EXAMINER:

/Brandon Fetterolf/

DATE CONSIDERED:

09/20/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. ARCD:390US	Serial No. 10/782,401
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Philip Ashton-Rickardt	
		Filing Date: February 19, 2004	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BF	C9	Hampson <i>et al.</i> , "A minimal serpin promoter with high activity in haematopoietic progenitors and activated T cells," <i>Hematol. J.</i> , 2:150-160, 2001.
	C10	Inglis <i>et al.</i> , "Isolation of two cDNAs encoding novel α 1-antichymotrypsin-like proteins in a murine chondrocytic cell," <i>Gene</i> , 106(2):213-220, 1991.
	C11	Liu <i>et al.</i> , "NF- κ B protects from the lysosomal pathway of cell death," <i>EMBO J.</i> , 22(19):5313-5322, 2003.
	C12	Morris <i>et al.</i> , "Murine serpin 2A is a redox-sensitive intracellular protein," <i>Biochem. J.</i> , 371(Pt 1):165-173, 2003.
↓	C13	Silverman <i>et al.</i> , "The serpins are an expanding superfamily of structurally similar but functionally diverse proteins," <i>J. Biol. Chem.</i> , 276(36):33293-33296, 2001.
BF	C14	Wyllie <i>et al.</i> , "Cell death: the significance of apoptosis," <i>Int. Rev. Cytol.</i> , 68:251-305, 1981.

25400625.1

EXAMINER: /Brandon Fetterolf/

DATE CONSIDERED: 09/20/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.
ARCD:390USSerial No.
10/782,401

List of Patents and Publications for Applicant's

Applicant
Philip Ashton-Rickardt

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
February 19, 2004Group:
1642U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
BF	A1	2004/0214773	10/28/04	Ashton-Rickardt	12	514	02/19/04

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
BF	B1	WO 99/57273	11/11/99	WIPO			YES

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BF	C15	Bird, "Regulation of pro-apoptotic leucocyte granule serine proteinases by intracellular serpins", <i>Immunology and Cell Biology</i> , 77: 47-57, 1999.
	C16	Guicciardi <i>et al.</i> , "Lysosomes in cell death.", <i>Oncogene</i> , 23:2881-2890, 2004.
	C17	Hamerman <i>et al.</i> , "Serpin 2a is induced in activated macrophages and conjugates to a ubiquitin homolog", <i>Journal of Immunology</i> , 168:2415-2423, 2002.
	C18	Liu <i>et al.</i> , "Induction of a cathepsin B inhibitor by NF-kB blocks the lysosomal pathway of cell death", <i>FASEB Journal</i> , 17: C152, 2003.
	C19	Liu <i>et al.</i> , "Serine protease inhibitor 2A inhibits caspase-independent cell death", <i>FEBS</i> , 569:49-53, 2004.
BF	C20	Morris <i>et al.</i> , "Nuclear localisation of haemopoietic serpin 2A: A potential regulatory of apoptosis", <i>British Journal of Haematology</i> , 101:27, 1998.

25621161.1

EXAMINER: /Brandon Fetterolf/

DATE CONSIDERED: 09/20/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)